Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2020 | 03-2019 | 03-2018 | 03-2017 | 03-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,866,049 | 6,318,837 | 2,650,698 | 2,970,931 | 3,746,836 |
| Marketable Securities | 145,562 | 209,484 | 725,814 | 527,152 | 901,380 |
| Receivables | 7,221,273 | 6,742,071 | 3,859,128 | 4,136,436 | 3,573,739 |
| Inventories | 6,988,311 | 8,880,696 | 1,916,496 | 2,104,534 | 2,108,283 |
| Other current assets | 2,497,575 | 5,304,832 | 557,136 | 1,985,107 | 1,072,192 |
| TOTAL | $22,718,770 | $27,455,920 | $9,709,272 | $11,724,160 | $11,402,430 |
| Non-Current Assets | |||||
| PPE Net | 12,754,600 | 11,848,780 | 4,831,209 | 4,930,414 | 4,580,903 |
| Investments And Advances | 3,398,986 | 2,762,091 | 2,739,465 | 2,906,678 | 1,545,377 |
| Intangibles | 75,291,780 | 81,195,940 | 18,391,608 | 19,423,478 | 12,636,285 |
| Other Non-Current Assets | 3,789,934 | 1,588,169 | 1,286,618 | 1,524,060 | 1,574,905 |
| TOTAL | $95,235,300 | $97,394,980 | $27,248,900 | $28,784,630 | $20,337,470 |
| Total Assets | $117,954,100 | $124,850,900 | $36,958,170 | $40,508,770 | $31,739,910 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 5,398,716 | 8,864,514 | 162 | 5,068,760 | 1,896,251 |
| Accounts payable and accrued liabilities | 2,933,107 | 2,946,546 | 2,162,331 | 2,237,794 | 1,586,039 |
| Other current liabilities | 10,005,250 | 9,711,954 | 3,865,842 | 4,741,661 | 3,274,574 |
| TOTAL | $20,018,260 | $22,598,380 | $6,637,581 | $12,704,650 | $7,114,868 |
| Non-Current Liabilities | |||||
| Long Term Debt | 41,459,680 | 42,894,050 | 8,870,796 | 5,578,717 | 4,480,008 |
| Other Non-Current Liabilities | 6,449,446 | 5,083,639 | 2,478,191 | 2,558,747 | 2,399,753 |
| TOTAL | $54,442,930 | $55,780,230 | $12,163,910 | $9,678,762 | $7,932,052 |
| Total Liabilities | $74,461,200 | $78,378,610 | $18,801,490 | $22,383,410 | $15,046,920 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | N/A | 118,250 | 1,589,377 | 1,581,042 | 1,580,568 |
| Common Shares | 15,346,730 | 14,792,260 | 701,226 | 606,388 | 537,558 |
| Retained earnings | 12,603,740 | 14,124,290 | 14,015,760 | 14,059,900 | 12,641,950 |
| Other shareholders' equity | 888,760 | 3,217,650 | 3,292,034 | 3,214,853 | 3,241,192 |
| TOTAL | $43,492,870 | $46,472,290 | $18,156,680 | $18,125,380 | $16,692,980 |
| Total Liabilities And Equity | $117,954,070 | $124,850,900 | $36,958,170 | $40,508,790 | $31,739,900 |